In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.09 below Vivos Therapeutics Inc average.

Within Medical Equipment & Supplies industry 182 other companies have achieved higher Quick Ratio than Vivos Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3555 to 3739.

Explain Quick Ratio?
How much Cash & cash equivalents VVOS�s has?
What are VVOS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VVOS Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	217.29 %	281.56 %	263.12 %	45.08 %	-3.27 %
Y / Y Cash & cash equivalent Change	-59.7 %	-9.91 %	-67.59 %	-51.09 %	-36.23 %
Quick Ratio MRQ	0.09	0.12	0.11	0.42	0.69
VVOS's Total Ranking	# 3739	# 3555	# 0	# 2180	# 1723
Seq. Current Liabilities Change	13.67 %	-0.77 %	143.05 %	15.73 %	36.69 %
Seq. Cash & cash equivalent Change	-15.92 %	3.99 %	-34.27 %	-29.87 %	87.96 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 183
Healthcare Sector	# 848
Overall Market	# 3739

Quick Ratio Statistics
High	Average	Low
6.58	1.61	0.08
(Jun 30 2021)		(Dec 31 2019)

Financial Statements
Vivos Therapeutics Inc 's Current Liabilities	$ 20 Millions	Visit VVOS's Balance sheet
Vivos Therapeutics Inc 's Cash & cash equivalent	$ 2 Millions	Visit VVOS's Balance sheet
Source of VVOS's Sales		Visit VVOS's Sales by Geography

Cumulative Vivos Therapeutics Inc 's Quick Ratio

VVOS's Quick Ratio for the trailling 12 Months

VVOS Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	200.69 %	132.54 %	47.64 %	-13.22 %	-27.21 %
Y / Y Cash & cash equivalent TTM Growth	-53.4 %	-46.7 %	-46.3 %	-7.88 %	59.04 %
Quick Ratio TTM	0.14	0.23	0.32	0.68	0.91
Total Ranking TTM	# 4128	# 4093	# 0	# 3027	# 3022
Seq. Current Liabilities TTM Growth	28 %	36.12 %	55.64 %	10.89 %	-1.01 %
Seq. Cash & cash equivalent TTM Growth	-22.6 %	-1.96 %	-26.29 %	-16.69 %	-11.46 %

Quick ratio ranking by company, industry and sector >> Back to VVOS Financial Strength Comparisons >> Go to Compare VVOS Quick Ratio to its Competitors

News about Vivos Therapeutics Inc Quick Ratio

Vivos Therapeutics: Pioneering Sleep Treatment Through Strategic Alliances and Private Equity Investment

Vivos Therapeutics: Revolutionizing Sleep Treatment with Strategic Alliance and Private Equity Investment
In a critical pivot towards enhancing revenue streams and potential profit, Vivos Therapeutics recently announced the closure of a momentous $7.5 million At-The-Market private equity-backed investment. Coupled with this exciting development, the leading sleep treatment provider has also launched a strategic marketing and distribution alliance in Colorado, marking a significant milestone in their innovative marketing and distribution model. This revolutionary move is set to redefine the landscape of sleep disorder treatment and position Vivos Therapeutics as a trailblazer in the industry.
Sleep disorders affect millions of individuals worldwide, with obstructive sleep apnea being one of the most prevalent conditions. Traditionally, the gold standard treatment for sleep apnea has been Continuous Positive Airway Pressure (CPAP) therapy, which involves wearing a mask over the nose and/or mouth during sleep to deliver a steady stream of air to keep the airways open. However, compliance rates for CPAP therapy have been alarmingly low due to discomfort, inconvenience, and even embarrassment associated with its usage.

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $20.39 millions, cumulative Quick Ratio decreased to 0.14 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 205 other companies have achieved higher Quick Ratio than Vivos Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 4093 to 4128.

Explain Quick Ratio?
How much Cash & cash equivalents VVOS�s has?
What are VVOS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 206
Healthcare Sector	# 912
Within the Market	# 4128

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.34	1.11	0.14
(Mar 31 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
U S Physical Therapy Inc	0.23	$ 24.887 Millions	$ 109.909 Millions
Accuray Incorporated	0.21	$ 40.623 Millions	$ 191.405 Millions
Cerus Corporation	0.21	$ 17.980 Millions	$ 85.790 Millions
Tenon Medical Inc	0.20	$ 1.677 Millions	$ 8.305 Millions
Bioventus Inc	0.19	$ 29.457 Millions	$ 154.471 Millions
Avita Medical Inc	0.19	$ 13.096 Millions	$ 68.714 Millions
Bausch and Lomb Corp	0.19	$ 367.000 Millions	$ 1,942.000 Millions
Dentsply Sirona Inc	0.18	$ 239.000 Millions	$ 1,319.000 Millions
Adm Tronics Unlimited Inc	0.18	$ 0.223 Millions	$ 1.235 Millions
Catheter Precision Inc	0.16	$ 1.839 Millions	$ 11.166 Millions
Zimmer Biomet Holdings Inc	0.14	$ 410.000 Millions	$ 3,013.500 Millions
Nexgel Inc	0.12	$ 1.692 Millions	$ 14.440 Millions
Ufp Technologies Inc	0.12	$ 9.045 Millions	$ 78.304 Millions
Solventum Corporation	0.11	$ 403.000 Millions	$ 3,663.000 Millions
Nakamoto Inc	0.11	$ 19.072 Millions	$ 179.474 Millions
Petvivo Holdings Inc	0.10	$ 0.135 Millions	$ 1.313 Millions
The Pennant Group Inc	0.10	$ 15.273 Millions	$ 152.406 Millions
Non Invasive Monitoring Systems Inc	0.10	$ 0.160 Millions	$ 1.607 Millions
Boston Scientific Corporation	0.10	$ 749.000 Millions	$ 7,530.000 Millions
Integer Holdings Corporation	0.10	$ 21.375 Millions	$ 217.141 Millions
Bellevue Life Sciences Acquisition Corp	0.10	$ 1.500 Millions	$ 15.734 Millions
National Vision Holdings Inc	0.09	$ 35.998 Millions	$ 383.026 Millions
Becton Dickinson And Company	0.09	$ 864.000 Millions	$ 9,404.000 Millions
Vivos Therapeutics Inc	0.09	$ 1.774 Millions	$ 20.389 Millions
The Cooper Companies Inc	0.08	$ 154.900 Millions	$ 1,866.600 Millions
Infusystem Holdings Inc	0.06	$ 0.964 Millions	$ 15.300 Millions
Vsee Health Inc	0.06	$ 0.454 Millions	$ 8.139 Millions
P3 Health Partners Inc	0.05	$ 21.272 Millions	$ 388.581 Millions
Henry Schein Inc	0.05	$ 157.000 Millions	$ 3,488.000 Millions
Yunhong Green Cti Ltd	0.04	$ 0.320 Millions	$ 8.371 Millions

Date modified: 2026-09-12T06:25:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.